Drug Profile
CBT 311
Alternative Names: CBT-311Latest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator COARE Biotechnology
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer; Colorectal cancer; Pancreatic cancer
Highest Development Phases
- Research Breast cancer; Colorectal cancer; Pancreatic cancer
Most Recent Events
- 22 Feb 2022 CBT 311 is still in research development for Pancreatic cancer, Colorectal cancer, and Breast cancer in USA (unspecified route) (COARE Biotechnology pipeline, February 2022)
- 04 Aug 2016 CBT 311 is available for licensing as of 04 Aug 2016. http://coarebiotechnology.com/
- 04 Aug 2016 Early research in Breast cancer in USA (unspecified route)